Apoptosis occurs independently of bcl-2 and p53 over-expression in non-small cell lung carcinoma

Histopathology

Volumn 29, Issue 1, 1996, Pages 45-50

  O'Neill, A J ^a   Staunton, M J ^a   Gaffney, E F ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Apoptosis; bcl 2 over expression; Non small cell lung carcinoma; p53 over expression

Indexed keywords

ADULT; AGED; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030057349     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1996.d01-478.x     Document Type: Article

References (50)

1. Wyllie AH. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview. Cancer Metast. Rev. 1992; 11; 95-103.
2. Leoncini L, Del Vecchio MT, Megha T et al. Correlations between apoptotic and proliferative indices in malignant non-Hodgkins lymphomas. Am. J. Pathol. 1993; 142; 755-763.
3. Gaffney EF. The extent of apoptosis in different types of high grade prostatic carcinoma. Histopathology 1994; 25; 269-274.
4. Staunton MJ, Gaffney EF. Tumor type is a determinant of susceptibility to apoptosis. Am. J. Clin. Pathol. 1995; 103; 300-307.
5. Stewart BW. Mechanisms of apoptosis: Integration of genetic, biochemical, and cellular indicators. J. Natl. Cancer Inst. 1994; 86; 1286-1296.
6. Canman CE, Kastan MB. Induction of apoptosis by tumor suppressor genes and oncogenes. Semin. Cancer Biol. 1995; 6; 17-26.
7. Hoffman B. Liebermann DA. Molecular controls of apoptosis: differentiation/growth arrest primary response genes, protooncogenes. and tumor suppressor genes as positive & negative modulators. Oncogene 1994; 9; 1807-1812.
8. Gazzeri S, Brambilla E. Caron de Fromentel C et al. p53 genetic abnormalities and myc activation in lung carcinoma. Int. J. Cancer 1994; 58; 24-32.
9. Mitsudomi T, Viallet J, Mulshine JL et al. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991; 6; 1353-1362.
10. Higashiyama M, Doi O, Kodama K et al. Retinoblastoma protein expression in lung cancer: an immunohistochemical analysis. Oncology 1994; 51: 544-551.
11. Quinlan DC, Davidson AG, Summers CL et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992; 52; 4828-4831.
12. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 1994; 54; 2496-2503.
13. Volm M, Mattern J, Hecker S, Pommerenke EW. Association of p53 expression with proliferative activity and poor prognosis in patients with squamous cell lung carcinomas. Int. J. Oncol. 1994; 5; 533-538.
14. Caamano J, Ruggeri B, Momiki S et al. Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines. Am. J. Pathol. 1991; 139; 839-845.
15. McLaren R, Kuzu I, Dunnill M et al. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br. J. Cancer 1992; 66; 735-738.
16. Marchetti A, Buttitta F, Merlo G et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res. 1993; 53; 2846-2851.
17. Walker C, Robertson LJ, Myskow MW et al. p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br. J. Cancer 1994; 70; 297-303.
18. Top B, Mooi WJ, Klaver SG et al. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int. J. Cancer 1995; 64; 83-91.
19. Carbone DP, Mitsudomi T, Chiba I et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1995; 106; 377S-381S.
20. Fujino M. Dosaka-Akita H, Kato M et al. Simultaneous use of the PCR-SSCP method and immunohistochemistry for increasing the detection efficacy of p53 abnormalities in human lung cancer. Am. J. Clin. Pathol. 1995; 104; 319-324.
21. Pezzella F, Turley H. Kuzu I et al. bel-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med. 1993; 329; 690-694.
22. Gaffney EF, O'Neill AJ, Staunton MJ. bcl-2 and prognosis in non-small cell lung carcinoma. N. Engl. J. Meb. 1994; 330; 1757-8.
23. Fleming MV, Guinee DG Jr, Chu WS et al. Correlates of bcl-2 immunohistochemical staining in a surgical series of lung cancer patients, Lab. Invest. 1995; 72; 148 A.
24. Fontanini G, Vignati S, Bigini D et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br. J. Cancer 1995; 71; 1003-1007.
25. Kastan MB. Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metast. Rev. 1995; 14; 3-15.
26. Wyllie AH. Death gets a brake, Nature 1994; 369; 272-273.
27. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80; 879-886.
28. Pezzella F, Gatter K. What is the value of bcl-2 protein detection for histopathologists? Histopathology 1995; 26; 89-93.
29. Gaffney EF, O'Neill AJ, Staunton MJ. In situ end-labelling, light microscopical assessment and ultrastucture of apoptosis in lung carcinoma. J. Clin. Pathol. 1995; 48; 1017-1021.
30. Cattoretti G, Pileri S, Parravicini C et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J. Pathol. 1993; 171; 83-98.
31. Lu Q-L, Poulsom R, Wong L, Hanby AM. BCL-2 expression in adult and embryonic non-haematopoietic tissues. J. Pathol. 1993; 169; 431-437.
32. LeBrun DP, Warnke RA, Cleary ML. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am. J. Pathol. 1993; 142; 743-753.
33. Chiou S-K. Rao L, White E, Bcl-2 blocks p53-dependent apoptosis. Mol. Cell Biol. 1994; 14; 2556-2563.
34. Krajewski S, Krajewska M, Shabaik A et al. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am. J. Pathol. 1994; 145; 1323-1336.
35. Kiefer MC, Brauer MJ, Powers VC et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995; 374; 736-739.
36. Boise LH, Gonzalez-Garcia M, Postema CE. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74; 597-608.
37. Jiang S-X, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J. Pathol. 1995; 177; 135-138.
38. Ben-Ezra JM, Kornstein MJ, Grimes M, Krystal G. Small cell carcinomas of the lung express the bcl-2 protein. Am. J. Pathol. 1994; 145; 1036-1040.
39. Bracey TS, Miller JC Preece A, Paraskeva C. γ-radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene 1995; 10; 2391-2396.
40. Lowe SW, Ruley HE, Jacks T, Houseman DE. p53-dependent apoptosis modulates the cytoxicity of anticancer agents. Cell 1993; 74; 957-967.
41. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 1993; 362; 847-849.
42. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild type p53 are more resistent to induction of apoptosis by some agents. Blood 1993; 82; 1092-1096.
43. Elledge R, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res. Treatment 1994; 32; 39-47.
44. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA. The WTI gene product stabilizes P53 and inhibits apoptosis. Genes and Development 1995; 9; 2143-2156.
45. Hall PA, Lane DP. p53 in tumor pathology: can we trust immunohistochemistry? - Revisited! J. Pathol. 1994; 172; 1-4.
46. Batsakis JG, El-Naggar AK. p53: fifteen years after discovery. Adv. Anat. Pathol. 1995; 2; 71-88.
47. Halevy O, Michalovitz D, Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990; 250; 113-116.
48. Forrester K, Lupold SE, Ott VL et al. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 1995; 10; 2103-2111.
49. Saegusa M, Takano Y, Wakabayashi T, Okayasu I. Apoptosis in gastric carcinomas and its association with cell proliferation and differentiation, Jpn J. Cancer Res. 1995; 86; 743-748.
50. Kobayashi M, Watanabe H, Ajioka Y, Yoshida M, Hitomi J, Asakura H. Correlation of p53 protein expression in colorectal neoplasia. Virchows Arch 1995; 427; 27-32.